Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Rezolute, Inc. Rezolute to Participate in the BTIG Virtual Biotechnology Conference July 31, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement June 27, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds June 24, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants June 13, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants June 13, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) May 21, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update May 15, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting April 23, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) March 06, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update February 13, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer January 24, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism January 23, 2024 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) December 13, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day November 17, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports First Quarter Fiscal 2024 Results November 13, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism October 17, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism October 11, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress September 14, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute to Participate in Upcoming Investor Conferences in September September 06, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism June 27, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress May 11, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema March 23, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert March 08, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress February 10, 2023 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema December 15, 2022 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress November 09, 2022 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute to Present at the Jefferies London Healthcare Conference November 01, 2022 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting October 20, 2022 From Rezolute, Inc. Via GlobeNewswire Tickers RZLT Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.